TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38258274

Group type: EXPERIMENTAL
Intervention: AZD9567 2 mg, 10 mg, 20 mg, 40 mg, 80 mg, 100 mg, 125 mg, or 155 mg (single-ascending dose study)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Prednisolone 60 mg (single-ascending dose study)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: AZD9567 10 mg (multiple-ascending dose study)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Prednisolone 20 mg (multiple-ascending dose study)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: AZD9567 20 mg, 40 mg, 80 mg, or 125 mg (multiple-ascending dose study)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Prednisolone 5 mg, 20 mg, or 40 mg (multiple-ascending dose study)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: AZD9567 (up to 80 mg)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Prednisolone 5 mg
Number of subjects: 149
Study: 38258329

Group type: EXPERIMENTAL
Intervention: Decitabine 20 mg/m² followed by cytarabine
Number of subjects: 0
Study: 38258362

Group type: EXPERIMENTAL
Intervention: Platelet reactivity measured using VerifyNow P2Y in patients with reduced LVEF (REF)
Number of subjects: 9319

Group type: COMPARATOR
Intervention: Platelet reactivity measured using VerifyNow P2Y in patients with preserved LVEF (PEF)
Number of subjects: 9319

Group type: EXPERIMENTAL
Intervention: High platelet reactivity (HPR) status in patients with LV dysfunction
Number of subjects: 9319
Study: 38258369

Group type: EXPERIMENTAL
Intervention: Belimumab 1 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SLE-DAS remission and LDA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38258434

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 0
Study: 38258563

Group type: EXPERIMENTAL
Intervention: 5 mg bolus of recombinant staphylokinase (r-SAK) before PCI
Number of subjects: 200

Group type: COMPARATOR
Intervention: Normal saline before PCI
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: r-SAK
Number of subjects: 200

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 200
Study: 38258566

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood pressure (SMBP) with usual care
Number of subjects: 3291

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 3291

Group type: EXPERIMENTAL
Intervention: Telemonitoring system
Number of subjects: 3291
Study: 38258600

Group type: EXPERIMENTAL
Intervention: APOE-ε2 genotype
Number of subjects: 4184

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 4184
Study: 38258673

Group type: EXPERIMENTAL
Intervention: Hip-focused physical therapy
Number of subjects: 184

Group type: COMPARATOR
Intervention: Spine-focused physical therapy
Number of subjects: 184
Study: 38258677

Group type: EXPERIMENTAL
Intervention: Low-dose naltrexone (6 mg)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 38258678

Group type: COMPARATOR
Intervention: Reference tocilizumab
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: BAT1806/BIIB800
Number of subjects: 621
Study: 38258823

Group type: EXPERIMENTAL
Intervention: Liver transplantation for iCCA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New molecular biomarkers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New technologies and strategies for graft availability
Number of subjects: 0
Study: 38258997

Group type: EXPERIMENTAL
Intervention: Liver surgery
Number of subjects: 2159
Study: 38259250

Group type: EXPERIMENTAL
Intervention: Pelabresib (CPI-0610) 225 mg tablet QD
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pelabresib (CPI-0610)
Number of subjects: 44
Study: 38259270

Group type: EXPERIMENTAL
Intervention: Yinqiao powder-maxing Ganshi decoction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38259304

Group type: EXPERIMENTAL
Intervention: Drug-eluting stent (DES)
Number of subjects: 8741

Group type: EXPERIMENTAL
Intervention: Rivaroxaban therapy
Number of subjects: 8741

Group type: EXPERIMENTAL
Intervention: Low hemoglobin level
Number of subjects: 8741

Group type: EXPERIMENTAL
Intervention: High WBC count
Number of subjects: 8741

Group type: EXPERIMENTAL
Intervention: Prior myocardial infarction (MI)
Number of subjects: 8741

Group type: EXPERIMENTAL
Intervention: Age ≥75 years
Number of subjects: 8741

Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 8741
Study: 38259459

Group type: EXPERIMENTAL
Intervention: LPCAT level in patients with SCAP
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: LPCAT level combined with PSI scores or CURB-65
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: On admission LPCAT level
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: LPCAT value combined with CURB-65 or PSI
Number of subjects: 299
Study: 38259542

Group type: EXPERIMENTAL
Intervention: Pediatric cGVHD Symptom Scale (PCSS)
Number of subjects: 180
Study: 38259555

Group type: EXPERIMENTAL
Intervention: Brunnsviken brief quality of life inventory (BBQ)
Number of subjects: 0
Study: 38259740

Group type: EXPERIMENTAL
Intervention: ACTIVA-MENTE program (active breaks) consisting of a 4-min, 30-s video with moderate to vigorous-intensity physical activity, taken 6 times a day for 6 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study: 38259747

Group type: EXPERIMENTAL
Intervention: sLiFE group intervention (strength and balance principles)
Number of subjects: 650

Group type: COMPARATOR
Intervention: Standard health advice
Number of subjects: 650
Study: 38259873

Group type: EXPERIMENTAL
Intervention: CoreDISTparticipation
Number of subjects: 29

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 29
Study: 38260556

Group type: EXPERIMENTAL
Intervention: Febuxostat (XOI) treatment for 48 weeks
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Febuxostat treatment
Number of subjects: 49

Group type: COMPARATOR
Intervention: Allopurinol (control)
Number of subjects: 49
Study: 38260663

Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg daily for 16 weeks
Number of subjects: 12
Study: 38261092

Group type: EXPERIMENTAL
Intervention: RV injury (isolated RV dilation)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: RV injury (dysfunction without RV dilation)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: RV injury (dysfunction with RV dilation)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: RV injury (acute cor pulmonale)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: RV injury (overall)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Day-28 mortality (with RV injury)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Combination of RV dysfunction with RV dilation or ACP
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: De novo RV injury
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: De novo RV injury after Day-14
Number of subjects: 118
Study: 38261093

Group type: EXPERIMENTAL
Intervention: Laser speckle contrast imaging (LSCI) during adenosine induced cardiac arrest (AiCA)
Number of subjects: 0
Study: 38261313

Group type: EXPERIMENTAL
Intervention: Pralsetinib (400 mg once daily, orally)
Number of subjects: 34
Study: 38261316

Group type: EXPERIMENTAL
Intervention: Avelumab at 10 mg/kg on days 1 and 15, ramucirumab at 8 mg/kg on days 1 and 15, paclitaxel at 80 mg/m2 on days 1, 8, and 15 every 4 weeks.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Avelumab with paclitaxel plus ramucirumab
Number of subjects: 60
Study: 38261319

Group type: EXPERIMENTAL
Intervention: Patient Priorities Care (PPC)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 264
Study: 38261323

Group type: EXPERIMENTAL
Intervention: 1 dose of naloxone (4 mg/0.1 mL) at 0, 2.5, 5, and 7.5 minutes
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 2 doses of naloxone at 0 and 2.5 minutes
Number of subjects: 21

Group type: COMPARATOR
Intervention: 1 dose of naloxone at 0 and 2.5 minutes (control)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 1 dose of naloxone at 0, 2.5, 5, and 7.5 minutes (test)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 2 doses of naloxone at 0 and 2.5 minutes (test)
Number of subjects: 21
Study: 38261372

Group type: EXPERIMENTAL
Intervention: Connected devices for home monitoring and education for early detection of pulmonary exacerbations (PEx).
Number of subjects: 20
Study: 38261390

Group type: EXPERIMENTAL
Intervention: Lupus low disease activity state (LLDAS) attained at least once
Number of subjects: 3811

Group type: EXPERIMENTAL
Intervention: LLDAS for at least 50% of observed time
Number of subjects: 3811

Group type: EXPERIMENTAL
Intervention: Remission attained
Number of subjects: 3811

Group type: EXPERIMENTAL
Intervention: Remission for at least 50% of observed time
Number of subjects: 3811

Group type: EXPERIMENTAL
Intervention: Modified remission glucocorticoid threshold (<5.0 mg/day prednisolone)
Number of subjects: 3811

Group type: EXPERIMENTAL
Intervention: Glucocorticoid-free remission
Number of subjects: 3811
Study: 38261392

Group type: EXPERIMENTAL
Intervention: Lupus anticoagulant positivity at inclusion
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Placental insufficiency
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Pre-existing maternal hypertension
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Antiphospholipid history
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Triple antiphospholipid antibody positivity
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Preterm delivery at 34 weeks or earlier
Number of subjects: 168
Study: 38261444

Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg twice daily and Uprosertib starting at 50 mg daily (doublet cohort)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg twice daily, Trametinib 2 mg daily, and Uprosertib 75 mg daily (triplet cohort)
Number of subjects: 27
Study: 38261469

Group type: EXPERIMENTAL
Intervention: Adhesive elastic tape
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard treatment (control)
Number of subjects: 23
Study: 38261535

Group type: EXPERIMENTAL
Intervention: Veverimer
Number of subjects: 1480

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1480
Study: 38261536

Group type: COMPARATOR
Intervention: Typical dialysis with dialysate temperature at 37°C (TD)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cold dialysis with dialysate temperature at 35°C
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Typical HD combined with a single exercise bout
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cold dialysis combined with a single exercise bout
Number of subjects: 10
Study: 38261579

Group type: EXPERIMENTAL
Intervention: Single oral dose of azithromycin (20 mg/kg)
Number of subjects: 32877
Study: 38261630

Group type: EXPERIMENTAL
Intervention: Extracorporeal Carbon Dioxide Removal (ECCO2R)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Invasive Ventilation
Number of subjects: 0
Study: 38261781

Group type: EXPERIMENTAL
Intervention: Various techniques used to assess bone health; specific interventions not detailed.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable; no specific intervention mentioned.
Number of subjects: 0
Study: 38261785

Group type: EXPERIMENTAL
Intervention: Microvideos
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional Lectures
Number of subjects: 60
Study: 38261893

Group type: EXPERIMENTAL
Intervention: Pharmacist-led program for HCV treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral medications (DAAs) initiation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Completion of DAAs treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cure (sustained virologic response)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Patient satisfaction with pharmacist experience
Number of subjects: 40
Study: 38261914

Group type: EXPERIMENTAL
Intervention: CO > 11 ppm in active smokers
Number of subjects: 1379

Group type: EXPERIMENTAL
Intervention: CO > 11 ppm in overall population
Number of subjects: 1379

Group type: EXPERIMENTAL
Intervention: Smoking in overall population
Number of subjects: 1379
Study: 38261958

Group type: EXPERIMENTAL
Intervention: Camrelizumab (200 mg intravenously, day one) + Apatinib (250 mg, q.d., five continuous days per week) + Nab-paclitaxel (135 mg/m2)
Number of subjects: 64
Study: 38261969

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG) plus Pembrolizumab
Number of subjects: 41
Study: 38261983

Group type: EXPERIMENTAL
Intervention: ADT + apalutamide
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: ADT + apalutamide + AAP
Number of subjects: 503

Group type: COMPARATOR
Intervention: ADT control
Number of subjects: 503
Study: 38262005

Group type: EXPERIMENTAL
Intervention: Sphenopalatine ganglion block (SPGB)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 83
Study: 38262066

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (81 mg daily)
Number of subjects: 640

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 640
Study: 38262242

Group type: EXPERIMENTAL
Intervention: Zanidatamab (ZW25)
Number of subjects: 16
Study: 38262275

Group type: EXPERIMENTAL
Intervention: Combination of low endothelial shear stress (ESS), high ESS gradient (ESSG), and high plaque structural stress (PSS) heterogeneity index (HI)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: High PSS HI
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: High ESSG
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Plaque burden >70%
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Combination of low ESS, high ESSG, and high PSS HI with plaque burden >70%
Number of subjects: 67
Study: 38262397

Group type: EXPERIMENTAL
Intervention: 6-week progressive resistance training protocol three times per week
Number of subjects: 11
Study: 38262428

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2 g intravenous once within 12 hours following tracheal intubation
Number of subjects: 345

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 345
Study: 38262462

Group type: EXPERIMENTAL
Intervention: Endoscopic management
Number of subjects: 0
Study: 38262617

Group type: EXPERIMENTAL
Intervention: Reassurance, education, lifestyle measures plus pharmacological strategies
Number of subjects: 111
Study: 38262642

Group type: EXPERIMENTAL
Intervention: 100 units incobotulinumtoxin-A
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 80
Study: 38262657

Group type: EXPERIMENTAL
Intervention: Specialised care at 'Maison des Femmes' (MdF)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Care at uncoordinated structures
Number of subjects: 67
Study: 38262864

Group type: EXPERIMENTAL
Intervention: Helfer skin tap technique
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study: 38262982

Group type: EXPERIMENTAL
Intervention: Tiko platform
Number of subjects: 1514
Study: 38263021

Group type: EXPERIMENTAL
Intervention: Amlodipine/benazepril 5/10 mg
Number of subjects: 560

Group type: COMPARATOR
Intervention: Benazepril/hydrochlorothiazide 10/12.5 mg
Number of subjects: 560
Study: 38263053

Group type: EXPERIMENTAL
Intervention: Prehabilitation (structured exercise training, nutritional counselling/therapy, psychological support) 2-3 sessions/week for at least 4 weeks before surgery
Number of subjects: 54
Study: 38263058

Group type: EXPERIMENTAL
Intervention: Surgery as initial management
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Endovascular revascularization
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Palliative care
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Overall in-hospital mortality
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: 90-day mortality
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Mortality for venous AMI
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Mortality for NOMI
Number of subjects: 705
Study: 38263073

Group type: EXPERIMENTAL
Intervention: Subclinical epileptiform activity (SEA) detection in AD subjects using LTM-EEG, hd-EEG, and MEG.
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: MEG for detecting SEA in AD subjects.
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: AD patients with SEA.
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: AD patients with SEA compared to those without SEA.
Number of subjects: 49

Group type: COMPARATOR
Intervention: Cognitively healthy controls (n=24).
Number of subjects: 49
Study: 38263088

Group type: EXPERIMENTAL
Intervention: Nurse-led telephonic case management
Number of subjects: 18

Group type: COMPARATOR
Intervention: Specialty, outpatient palliative care
Number of subjects: 18
Study: 38263142

Group type: EXPERIMENTAL
Intervention: mf-ERG amplitudes of N1, P1 and N2 in ring 1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Central macular thickness (CMT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Integrity of IS/OS junction
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: mf-ERG latencies in ring 1
Number of subjects: 40
Study: 38263188

Group type: EXPERIMENTAL
Intervention: Machine learning based prediction model (RISK)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38263241

Group type: EXPERIMENTAL
Intervention: Ultra-low-frequency pressure reactivity index (UL-PRx)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Cerebral intracranial pressure (ICP)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Cerebral perfusion pressure (CPP)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Delta CPP optimal (ΔCPPopt)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: In-hospital mortality
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: 12-month mortality
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Glasgow Outcome Scale Extended (GOSE)
Number of subjects: 263
Study: 38263321

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg orally once a day and durvalumab 1500 mg once every 3 weeks
Number of subjects: 0
Study: 38263353

Group type: EXPERIMENTAL
Intervention: Ritlecitinib (≥ 30 mg); median exposure: 169 days in placebo-controlled cohort, 624 days in all-exposure cohort.
Number of subjects: 1294

Group type: EXPERIMENTAL
Intervention: Ritlecitinib (≥ 30 mg); median exposure: 624 days in all-exposure cohort.
Number of subjects: 1294

Group type: COMPARATOR
Intervention: Placebo; median exposure: 169 days in placebo-controlled cohort.
Number of subjects: 1294
Study: 38263486

Group type: EXPERIMENTAL
Intervention: EGFR BATs (anti-CD3 x anti-EGFR bispecific antibody armed T cells) in combination with radiation and temozolomide (TMZ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EGFR BATs at the maximum feasible dose of 80 × 10
Number of subjects: 0
Study: 38263652

Group type: EXPERIMENTAL
Intervention: Subcutaneous iscalimab (3 mg/kg)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Intravenous iscalimab (10 mg/kg)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 38263964

Group type: EXPERIMENTAL
Intervention: Pancreatic infection management
Number of subjects: 0
Study: 38263993

Group type: EXPERIMENTAL
Intervention: Higher perceived social support (PSS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower perceived social support (PSS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stable moderate-to-high PSS (3.98 on a scale of 1 to 5)
Number of subjects: 0
Study: 38264276

Group type: EXPERIMENTAL
Intervention: 5-mcg norepinephrine
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: 10-mcg norepinephrine
Number of subjects: 155
Study: 38264323

Group type: EXPERIMENTAL
Intervention: Pimavanserin
Number of subjects: 795

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: Background antipsychotic
Number of subjects: 795
Study: 38264360

Group type: EXPERIMENTAL
Intervention: Dulaglutide (1.5 mg)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 255
Study: 38264365

Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Education Program (DiPEP)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Control
Number of subjects: 291
Study: 38264520

Group type: EXPERIMENTAL
Intervention: Enzalutamide as first line treatment for mCRPC
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: ARv7 detection
Number of subjects: 68
Study: 38264632

Group type: EXPERIMENTAL
Intervention: Two doses of oral psilocybin (first dose: 25 mg; second dose: 25 or 30 mg) paired with non-directive support
Number of subjects: 30

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 30
Study: 38264697

Group type: EXPERIMENTAL
Intervention: CURATE.AI-assisted dose titration
Number of subjects: 45

Group type: COMPARATOR
Intervention: Home blood pressure monitoring (active control; HBPM)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 45
Study: 38264861

Group type: EXPERIMENTAL
Intervention: Andexanet alfa
Number of subjects: 243

Group type: COMPARATOR
Intervention: Non-specific treatments (tranexamic acid or placebo ± prothrombin complex concentrate)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Non-specific treatments
Number of subjects: 243
Study: 38264869

Group type: EXPERIMENTAL
Intervention: Rucosopasem 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38264938

Group type: EXPERIMENTAL
Intervention: Ultrasound-facilitated catheter-directed thrombolysis (USCDT) with mean alteplase (r-tPA) infusion duration of 10.5 hours and mean total r-tPA dose of 18.1 mg.
Number of subjects: 489
Study: 38265029

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (prescribed to 30.8% of children)
Number of subjects: 266

Group type: COMPARATOR
Intervention: No antibiotic treatment (not prescribed to 69.2% of children)
Number of subjects: 266
Study: 38265318

Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 19

Group type: COMPARATOR
Intervention: Passive orthostasis
Number of subjects: 19
Study: 38265436

Group type: EXPERIMENTAL
Intervention: Contraction-type lymphatic vessels (LVs)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Noncontraction-type lymphatic vessels (LVs)
Number of subjects: 83